We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.33B
AUM Growth
-$894M
Cap. Flow
-$58.7M
Cap. Flow %
-2.52%
Top 10 Hldgs %
69.04%
Holding
126
New
9
Increased
16
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$35M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
SLRN
ACELYRIN
SLRN
+$13.8M
4
IMGN
Immunogen Inc
IMGN
+$12.4M
5
SGMT icon
Sagimet Biosciences
SGMT
+$12.3M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$41.1M
2
SAGE
Sage Therapeutics
SAGE
+$23.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$15.2M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.42%
2 Consumer Discretionary 42.85%
3 Miscellaneous 1.65%
4 Technology 0.61%
5 Communication Services 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
76
Ironwood Pharmaceuticals
IRWD
$674M
$1.06M 0.05%
110,532
– –
DDOG icon
77
Datadog
DDOG
$81.4B
$1.05M 0.04%
11,500
+6,500
+130% +$643K
XLO icon
78
Xilio Therapeutics
XLO
$58.8M
$950K 0.04%
32,143
– –
ADAP
79
DELISTED
Adaptimmune Therapeutics
ADAP
$884K 0.04%
1,133,775
– –
GOOGL icon
80
Alphabet (Google) Class A
GOOGL
$4.21T
$720K 0.03%
5,500
+1,500
+38% +$194K
CRIS icon
81
Curis
CRIS
$2.76M
$692K 0.03%
5,250
+2,000
+62% +$515K
XYZ
82
Block Inc
XYZ
$47.1B
$686K 0.03%
+15,500
New +$960K
ME
83
DELISTED
23andMe Holding Co
ME
$646K 0.03%
33,050
– –
AMD icon
84
Advanced Micro Devices
AMD
$830B
$617K 0.03%
6,000
– –
CRBU icon
85
Caribou Biosciences
CRBU
$137M
$504K 0.02%
105,347
– –
NFLX icon
86
Netflix
NFLX
$323B
$485K 0.02%
+12,850
New +$545K
CYCN
87
DELISTED
Cyclerion Therapeutics
CYCN
$475K 0.02%
138,955
– –
HARP
88
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$403K 0.02%
100,000
– –
CRWD icon
89
CrowdStrike
CRWD
$241B
$335K 0.01%
8,000
-6,000
-43% -$233K
INTA icon
90
Intapp
INTA
$2.83B
$335K 0.01%
+10,000
New +$365K
PEGA icon
91
Pegasystems
PEGA
$6.26B
$326K 0.01%
+15,000
New +$367K
LVTX
92
DELISTED
LAVA Therapeutics
LVTX
$294K 0.01%
200,000
– –
PCOR icon
93
Procore
PCOR
$8.29B
$294K 0.01%
4,500
– –
PYPL icon
94
PayPal
PYPL
$45.8B
$292K 0.01%
+5,000
New +$326K
BEAM icon
95
Beam Therapeutics
BEAM
$2.4B
$264K 0.01%
10,975
– –
HIPO icon
96
Hippo Holdings
HIPO
$843M
$191K 0.01%
24,000
– –
ALNY icon
97
Alnylam Pharmaceuticals
ALNY
$32.6B
$166K 0.01%
936
– –
ARWR icon
98
Arrowhead Research
ARWR
$10.7B
$146K 0.01%
5,440
– –
SQZ
99
DELISTED
SQZ Biotechnologies Company
SQZ
$129K 0.01%
1,606,309
– –
KA
100
DELISTED
Kineta, Inc. Common Stock
KA
$106K ﹤0.01%
31,055
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2023 Portfolio in Review

As of Q3 2023, Artal Group held 126 positions worth $2.33B, down 28% from $3.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group's Q3 2023 filing shows 9 new, 16 increased, 12 reduced and 23 closed positions. Its largest new stake was Neumora Therapeutics: 2,802,702 shares worth $39.5M. The largest sale was Krystal Biotech, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 55% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q3 2023 buy was Neumora Therapeutics: 2,802,702 shares worth $39.5M.
  • Artal Group added most to Apellis Pharmaceuticals in Q3 2023, an estimated $27M increase.
  • Artal Group's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $8.06M.
  • Artal Group fully exited Krystal Biotech in Q3 2023, selling an estimated $41.1M.
  • Artal Group's ten largest holdings make up 69% of its $2.33B portfolio in Q3 2023.
  • Artal Group opened 9 new positions and closed 23 in Q3 2023.
  • Artal Group's portfolio value fell 28% quarter-over-quarter to $2.33B.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.